Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Acne
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Acne
    Combination Gel Controls Propionibacterium acnes Without Irritation or Development of Microbial Resistance: Presented at EADV - (DGDispatch)
    Benzoyl Peroxide Plus Clindamycin Gel Improves Quality of Life in Patients With Mild to Moderate Acne: Presented at EADV - (DGDispatch)
    Patient-Reported Outcomes Favourable With Clindamycin Phosphate Plus Benzoyl Peroxide Gel for Acne Treatment: Presented at AAD - (DGDispatch)
    Clindamycin Phosphate, Benzoyl Peroxide Combination Improves Severe Acne: Presented at AAD - (DGDispatch)
    Three-Step System Effective for Acne Treatment Without Use of Antibiotic: Presented at AAD - (DGDispatch)

    News archive

     Recent webcasts/CME - Acne
      What Lies Beneath: Taking a Deeper Look at Acne Patient Care Strategies

      Webcasts/CME archive

       Recent cases - Acne
        Interstitial Pneumonia and Hepatitis Caused by Minocycline
        Minocycline-Induced Hyperpigmentation of the Tongue

        Cases archive
          




        my personal edition > acne > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Long-Term Spironolactone Appears Safe For Acne Treatment In Women

        A DGReview of :"Long-Term Safety of Spironolactone in Acne: Results of an 8-Year Followup Study"
        Journal of Cutaneous Medicine and Surgery

        02/13/2003
        By Robert Short


        The long-term use of spironolactone to treat acne in women appears to be safe, according to results of a long-term study.

        Side effects to the medication are common, but they do not appear to be a usual cause of stopping treatment. These were the overall conclusions of a study by Dr James Shaw (Division of Dermatology, University of Toronto, Toronto Western Hospital, Canada) and Dr Lucile White (Department of Medicine, MacNeal Hospital, Berwyn, Illinois, United States).

        Although spironolactone has been used for over 20 years as antiandrogen therapy in the treatment of acne and hirsuitism, the authors say that no long-term studies of the safety of the drug in this use have been published. Dr Shaw and Dr White completed this study of 91 women who were followed for up to 8 years.

        Initially, 210 patients were sent a survey questionnaire. In all, 91 completed surveys were put forward for analysis, representing 506 person-years of follow up and 200 person-years of spironolactone exposure. The mean treatment time was 28.5 months (range 0.5 to 122 months).

        The researchers say, "During the 8-year follow up period, there were no cases of serious illness attributable to spironolactone use". However, he added, 59% of patients had side effects. These side effects resulted in stopping therapy in 15% of patients. The most common side effects were the diuretic effect, and menstrual irregularities.
        J Cutan Med Surg. 2002 Nov-Dec;6:6:541-5. "Long-Term Safety of Spironolactone in Acne: Results of an 8-Year Followup Study"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2010 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send